Nociception

Nociception is the sensory process that provides the signals that lead to pain. This occurs through nociceptors, primary sensory neurons that are activated by stimuli that cause tissue damage. Stimuli can include tissue injury, extremes of heat and noxious chemicals. Unlike other sensory neurons that detect vision or taste, nociceptors are located all around the body, particularly under the skin, however, they are notably absent from the brain.

Nociception Products Targets

Products for Nociception - Page 5

Cat.No. Product Name Information/Activity
BCC7966 JZL 195 JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively.
BCC1718 LY2183240 LY2183240 is a novel and highly potent blocker of anandamide uptake (IC50 = 270 pM).
BCC7187 Palmitoylisopropylamide 189939-61-5
BCC2326 PF-3845 PF-3845 is a selective fatty acid amide hydrolase (FAAH) inhibitor (Ki = 0.23 μM); showing negligible activity against FAAH2.
BCC7641 PF 750 PF 750 is a selective and covalent fatty acid amide hydrolase (FAAH) inhibitor, with IC50s varied from 16.2-595 nM in different pre-incubation times. Covalently modifies the enzyme’s active site serine nucleophile.
BCC6289 SA 47 SA 47 is a selective and potent inhibitor of fatty acid amide hydrolase (FAAH) and carbamate.
BCC6280 SA 57 SA57 is a potent, selective FAAH inhibitor with IC50s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases MAGL (IC50s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC50 of 850 nM), but not other brain serine hydrolases.
BCC5609 TAK 21d 1143578-94-2
BCC6147 TC-F 2 1304778-15-1
BCC2324 URB597 URB597 is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets.